Dr. Trevor Campbell, MD, CCFP
Dr. Trevor Campbell, MD, CCFP
Northwestern Kellogg, Craig Garthwaite (Director of Healthcare at Kellogg): 2026 Healthcare Predictions
Northwestern Kellogg, Craig Garthwaite (Director of Healthcare at Kellogg): 2026 Healthcare Predictions
Northwestern Kellogg, Craig Garthwaite (Director of Healthcare at Kellogg): 2026 Healthcare Predictions
Thursday 29th January 2026
Craig Garthwaite discusses AI's role in drug development, GLP-1s, and healthcare economics for 2026.
44 minutes
Informative
Engaging
Inspiring
Educational
Honest
About this podcast
Author:
Dr. Trevor Campbell, MD, CCFP
Overview:
Categories:
Holistic Health Innovations
Mindfulness & Technology in Health
Mindful Recovery
Healing from Sexual Trauma
Innovative Treatments & Recovery Paths
Links:
Visit site
Episodes:
100 (View all)
Do you want to link to this podcast?
Get the buttons here!Healthcare in 2026: Predictions and Possibilities
Episode Overview
- AI's potential to lower drug development costs but uncertainty if savings will reach consumers.
- GLP-1s could reshape patient adherence and revenue streams.
- Medicare Advantage faces strategic adaptations due to economic pressures.
- Inflation Reduction Act might skew drug pipeline priorities.
- Large language models could impact healthcare optimisation and regulation.
"If all we get is cheaper drug development, but we don't get a large number of new drugs, then those gains should largely accrue to the pharmaceutical company."
How do people cope with the challenges of staying sober? In this episode of Healthscape, Craig Garthwaite, a leading applied economist and Director of Healthcare at Kellogg, sits down with MBA students Ashley Lemon and Kaiya Adam to forecast the healthcare landscape in 2026. The trio tackles a myriad of topics, from the anticipated impact of AI on drug development to the intricate economics of hospital systems.
Garthwaite doesn't shy away from discussing how AI could potentially reduce drug costs, but also questions if those savings will ever reach consumers. He brings a critical eye to the conversation, examining the role of GLP-1s in the market and their potential to transform patient adherence and revenue trajectories. The episode also explores the evolving dynamics of Medicare Advantage and Medicaid markets, highlighting potential shifts in strategies due to economic pressures and policy changes.
Garthwaite's candid views on the Inflation Reduction Act reveal concerns about its long-term effects on drug pipelines and market strategies. As the discussion unfolds, listeners are treated to a thought-provoking dialogue on how healthcare policy and economic forces intersect. With light-hearted humour peppered throughout, the episode offers a blend of expert analysis and engaging banter that keeps you hooked from start to finish.
Whether you're a healthcare professional or just curious about the future of healthcare, this episode promises to leave you with plenty to ponder. What are your thoughts on how AI might change the future of drug development?